Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammatory regimens for hospitalized COVID-19
IRCT20200318046812N2Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydroxychloroquine, azithromycin, prednisolone, naproxen and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoints: Admission to ICU, In-hospital mortality and 9 more. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquineazithromycinprednisolonenaproxenlopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200318046812N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200318046812N2.